產品資訊 - Clinical Meningococcal Polysaccharide Vaccine->aspalthic products

登入

加入會員

求助

Changchun Changsheng Life Sciences Ltd.

	Recommended Results

Clinical Meningococcal Polysaccharide Vaccine

產品分類 :

化學->化學用品->aspalthic products

Clinical Meningococcal Polysaccharide Vaccine

產品規格

Model No:	0.5ml/vial

Country	CN
Minimum Order	5000
Payment Term	L/C,T/T

產品描述

The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic Neisseria meningitidis serogroups A,C,Y,W135.


 [Description] 
The vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of Neisseria meningitidis group ACYW135 respectively and Iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying Phosphate buffered saline (PBS) immediately, and turn into a clear liquid after reconstitution. 
Active constituent: Neisseria meningitidis group ACYW135 capsular polysaccharides. 
Subsidiary materials: All the components of subsidiary materials approved shall be listed. 
Vaccine diluent: Sterile, pyrogen-free PBS. 
[Specifications] 
0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing  200μg of meningococcal polysaccharide (50μg of each polysaccharide of group A,C,Y,W135).


[Administration and dosage] 
(1) Reconstitute the vaccine with the accompanying PBS as the stated value. Shake and inject immediately. 
(2) The vaccine shall be injected s.c. at deltoid insertion area of the lateral upper arm. 
(3) One single human dose of 0.5 ml vaccine is required. The immunization shall be carried out before the epidemic season of epidemic cerebrospinal meningitis. 
[Adverse reactions] 
Common adverse reactions: 
(1) Pain, tenderness, mild or moderate erythema, swelling and infiltration at the injection site within 24 hours after vaccination, which can subside spontaneously within 2-3 days in most cases. 
(2) Transient fever may occur after vaccination, most of which are mild, can be relieved spontaneously within 1-2 days, and need no particular treatment. The recipients with moderate fever or the fever lasting for more than 48 hours may 
receive symptomatic treatment. 
Rare adverse reactions: 
(1) Severe fever: Symptomatic treatment shall be given to prevent febrile convulsion. 
(2) Serious erythema and, swelling at the injection site or other complications: symptomatic treatment shall be given. 
Extremely rare adverse reactions: 
(1) Allergic rash: Rash may occur with 72 hours after vaccination. Antianaphylactic treatment should be given to the recipients with rash promptly. 
(2) Anaphylactic shock: Anaphylactic shock may occur within one hour after vaccination.  Emergency treatment including injection with adrenaline shall be given promptly. 
(3) Allergic purpura: Antianaphylactic treatment with corticosteroid should be given to the recipients with allergic purpura. Give anti-allergic treatment with cortical steroids. If the treatment is inappropriate or delayed, purpura nephritis may be complicated. 
(4) Angioneurotic edema and allergic neuritis may occur occasionally. 
(5) Allergic exfoliative dermatitis cases have been reported occasionally. 
 
[Feature] 
Fill a gap in our country for the first time by developing 4-valent vaccine . 
Improve traditional purification technology to eliminate nucleic acid and protein. 
Improve WHO specifications and high harvest rate. Develop new type of stabilizer. Improve national quality standards. 
 
1.Group ACYW135                              
2.Group A+C                                       
3.prevent epidemic cerebrospinal meningitis                                                   


4.purified capsular polysaccharide antigens  
<img src="http://i.bosscdn.com/product/18/f2/13/d46381b9bd8edf65b150508726.png@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="-ACYW135" alt="-ACYW135" /> 
 



 
ccls-vaccine.com

其他類似產品